These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27594510)

  • 1. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
    Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
    Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
    Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
    Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
    Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
    Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
    Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
    Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
    Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions.
    Leivo MZ; Tacha DE; Hansel DE
    Hum Pathol; 2021 Jul; 113():28-33. PubMed ID: 33887302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
    Hoang LL; Tacha DE; Qi W; Yu C; Bremer RE; Chu J; Haas TS; Cheng L
    Arch Pathol Lab Med; 2014 Jul; 138(7):943-9. PubMed ID: 24978921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma.
    Gailey MP; Bellizzi AM
    Am J Clin Pathol; 2013 Dec; 140(6):872-80. PubMed ID: 24225756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
    Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
    Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression level of preoperative serum Uroplakin III is associated with biologically aggressive bladder cancer.
    Tsumura H; Matsumoto K; Ikeda M; Yanagita K; Hirano S; Hagiwara M; Nagashio R; Fujita T; Sato Y; Iwamura M
    Asian Pac J Cancer Prev; 2015; 16(4):1539-43. PubMed ID: 25743828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
    Mirsadraei L; Hodkoff A; Jones K; Shabaik A; Kader AK; Saenz CC; Montironi R; Tacha DE; Fadare O; Hansel DE
    Arch Pathol Lab Med; 2018 Feb; 142(2):168-177. PubMed ID: 28795841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
    Ren S; Klump W
    Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
    Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive micropapillary urothelial carcinoma of the bladder.
    Lopez-Beltran A; Montironi R; Blanca A; Cheng L
    Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.
    Miyamoto H; Izumi K; Yao JL; Li Y; Yang Q; McMahon LA; Gonzalez-Roibon N; Hicks DG; Tacha D; Netto GJ
    Hum Pathol; 2012 Nov; 43(11):2033-40. PubMed ID: 22607700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.